BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
197 results:

  • 1. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
    Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Deciphering the heterogeneity of neutrophil cells within circulation and the lung cancer microenvironment pre- and post-operation.
    Liu F; Liu X; Liu Y; Chen D; Liu X; Qin C; Song Y; Fang H; Wu D
    Cell Biol Toxicol; 2024 Feb; 40(1):11. PubMed ID: 38319415
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small cell lung cancer.
    Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
    Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
    Tantawy MN; McIntyre JO; Yull F; Calcutt MW; Koktysh DS; Wilson AJ; Zu Z; Nyman J; Rhoades J; Peterson TE; Colvin D; McCawley LJ; Rook JM; Fingleton B; Crispens MA; Alvarez RD; Gore JC
    Cancer Med; 2024 Feb; 13(3):e6812. PubMed ID: 38239047
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
    Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Real-World Clinical Outcomes for Patients with
    Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
    Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with her2 exon 20 insertion mutation: a case report.
    He X; Hou L; Bai J; Sun C; Wang D; An G
    Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy.
    Hu WT; Zhang Q; Zhang Z; He X; Zhou M; Guo Y; Wang X
    Front Immunol; 2023; 14():1112409. PubMed ID: 36949952
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Clinicopathological features of patients with RET fusion-positive non-small cell lung cancer].
    Tan Q; Ji Y; Wang XL; Wang ZW; Qi XW; Liu YK
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):124-128. PubMed ID: 36748131
    [No Abstract]    [Full Text] [Related]  

  • 12. The expression of her2/neu in patients with lung cancer and its associated factors.
    Lashkarizadeh M; Lashkarizadeh M; Nikian M; Kouhestani Parizi M
    Clin Respir J; 2023 Feb; 17(2):90-95. PubMed ID: 36617420
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Transcriptomic FHIT
    Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
    Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Chinese expert consensus on the diagnosis and treatment of her2-altered non-small cell lung cancer.
    Zhang S; Wang W; Xu C; Zhang Y; Cai X; Wang Q; Song Z; Li Z; Yu J; Zhong W; Wang Z; Liu J; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Dong X; Pang F; Wang K; Yao C; Lin G; Li S; Yang Z; Luo J; Jia H; Nie X; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Xia Y; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Gao W; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Yu G; Shi L; Xia Y; Gao F; Zhang X; Xu T; Zhou W; Wang H; Liu Z; Yang N; Wu L; Wang Q; Wang G; Hong Z; Wang J; Fang M; Fang Y; Zhang Y; Song Y; Ma S; Fang W; Lu Y
    Thorac Cancer; 2023 Jan; 14(1):91-104. PubMed ID: 36444143
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
    Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
    Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Outcome of Patients With Resected Early-Stage Non-small cell lung cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
    Mordant P; Brosseau S; Milleron B; Santelmo N; Fraboulet-Moreau S; Besse B; Langlais A; Gossot D; Thomas PA; Pujol JL; Ricordel C; Madelaine J; Lamy R; Audigier-Valette C; Missy P; Blons H; Barlesi F; Westeel V;
    Clin Lung Cancer; 2023 Jan; 24(1):1-10. PubMed ID: 36180314
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having her2 alterations.
    Zhuo X; Guo H; Ma J; Lai J; Liu L; Yin K; Zhao J; Wang J; Jiang F; Xu W; Yuan X; Lin X; Fu G
    J Cancer Res Clin Oncol; 2023 May; 149(5):2029-2039. PubMed ID: 35829744
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Portuguese Consensus Recommendations for Next-Generation Sequencing of lung cancer, Rare Tumors, and cancers of Unknown Primary Origin in Clinical Practice.
    R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
    Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.